Ahmed A Zeeneldin, Magdi M Saber, Ashraf H Hassouna and Sara A Farag
Accepted Abstracts: J Cancer Sci Ther
The current developments in SPECT (CT) and PET (CT) imaging have put a step forward in personalized radionuclide therapeutic medicine in particular reference to a wide variety of malignant conditions. The factors affecting such a targeted radionuclide therapy include fraction of absorbed radionuclide, radiosensitivity, degree of uptake, locoregional distribution as well as intratumoural retention pattern of radiopharmaceuticals administered which can be further optimized by bringing the radionuclide in the close vicinity of the tumour cell as well as selective targeting with radionuclide possessing particulate emission and a gamma emission to permit simultaneous imaging. The radiolabels of choice would be Re-188, Sm-153, Lu-177 and Ho-166. There are many other emerging radionuclides with promising characteristics and can offer optimized therapeutic efficacy in a wide variety of malignant conditions using MIBG-I 131 therapy, intrarterial therapy, intracavitary therapy, radioimmunotherapy, radiopeptide therapy and labeled hormone therapy. After systematic and dedicated use of such innovative and systemic radionuclide therapy, the monitoring of therapy response can also be effectively achieved by using PET CT imaging. This would enable further optimization of therapeutic index of emerging radionuclide therapy with reference to malignant deseases.
A. K. Shukla has done his Ph.D. in Biomedical Physics and has been engaged in research in the areas of medical physics, radiation safety, radiation dosimetry in nuclear medicine and diagnostic imaging and has published more than 65 papers apart from about ten book chapters. He has served as members of expert group in IAEA as well as many other national and international organizations. He is currently on the editorial board of journal of Medical Physics and is a referee to many prestigious journals. He is a member in governing body of a tertiary care institute.